Why the study?
Are multiple oral doses of apixaban safe and what are their pharmacokinetic and pharmacodynamic profiles in healthy subjects?
Are multiple oral doses of apixaban safe and what are their pharmacokinetic and pharmacodynamic profiles in healthy subjects?
Multiple oral doses of apixaban demonstrated a favorable safety profile, predictable pharmacokinetics, and dose-dependent pharmacodynamics in healthy subjects.
Supports further clinical development of apixaban; extends Phase 1 evidence for oral factor Xa inhibition.
Multiple oral doses of apixaban were safe and well tolerated over a 10-fold dose range, with pharmacokinetics with low variability and concentration-related increases in clotting time measures.
No takes yet. Share an insight, caveat, or question.
Frost et al. (2013) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: